- How did Pfizer up its COVID-19 vaccine capacity? 'Out of the box manufacturing,' CEO says
- Boehringer partners with Google to bring quantum computing to biopharma R&D
- Biogen bullish on Alzheimer's drug approval, sees Lilly data as positive despite AdComm rejection
- 'Very soon,' says Johnson & Johnson CEO as world waits for its COVID-19 vaccine data
- Bluebird to spin off cancer therapies into new company
- Merck is 'not complacent, but we're not desperate' for deals, CEO says
- Sanofi pays $125M to take lead in new checkpoint inhibitor space
- Regeneron execs say 'it's a problem' how few COVID-19 patients are getting antibody treatments
- What does a virtual J.P. Morgan healthcare conference mean for the future of the meeting? Executives weigh in
- Gilead's Veklury, now used in half of hospitalized U.S. COVID-19 patients, delivers multibillion-dollar revenue bump
- CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran
- Teladoc to pilot CGMs in Type 2 diabetes as Dexcom eyes new growth market
- Alexion gives an updated look at what AstraZeneca's getting for $39B
- Deal-making still a 'top priority' at Bristol Myers as CEO eyes midsize buys
- Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works
- Illumina inks multiple cancer diagnostic partnerships to complement upcoming Grail acquisition
- Sanofi's new chief digital officer steps up ambitions in marketing, research and even e-commerce
- Alnylam CEO outlines aggressive plan to catapult into biotech's top 5
- Will the first COVID-19 vaccines deter future launches? Not at all, experts say
- Vaccines aren't enough. We need more COVID-19 treatments, too
Featured Story | By Carly Helfand Earlier this week, Pfizer partner BioNTech upped the pair’s 2021 COVID-19 output projection to 2 billion doses for 2021, up from a previous estimate of up from a previous estimate of 1.3 billion. But how will the companies get there? By doing things “very differently and very out of the box in manufacturing,” CEO Albert Bourla explained Tuesday. read more |
| |
|---|
|
Top Stories By Conor Hale Through a new partnership with Google, Boehringer Ingelheim hopes to harness quantum computing to simulate the body’s molecular mechanics. read more By Ben Adams Biogen’s C-suite remains bullish that its controversial Alzheimer’s disease drug aducanumab will be approved in the coming weeks, citing a rare glimmer of hope from a similar drug from Eli Lilly that posted broadly positive data today. read more By Eric Sagonowsky J&J is in the “final stages” of data analysis for its phase 3 COVID-19 vaccine trial, CEO Alex Gorsky said Monday. And that could be a "game-changer," as Operation Warp Speed's Moncef Slaoui recently put it. The company's one-dose regimen could accelerate and simplify a faltering immunization push. read more By Nick Paul Taylor Bluebird bio is planning to spin off its oncology assets into a new publicly traded company. The move follows a series of operational missteps that have delayed patient access to once-hyped therapies. read more By Carly Helfand Merck CEO Ken Frazier gets why investors are worried about what will happen when megablockbuster cancer drug Keytruda eventually loses patent protection. He just doesn’t think they need to be as worried as they are. read more By Nick Paul Taylor Sanofi is paying Biond Biologics $125 million upfront for global rights to a novel immune checkpoint inhibitor. The agreement gives Sanofi a near-clinical anti-ILT2 monoclonal antibody designed to turn the innate and adaptive immune systems against tumors. read more By Carly Helfand To Regeneron, there’s no question about it: “We as a society have to do a much better job” of getting antibody therapies—such as the company’s own—to patients, R&D chief George Yancopoulos said Monday at the J.P. Morgan Healthcare Conference. read more By Amirah Al Idrus This year's virtual J.P. Morgan healthcare conference could be a "reset" that changes the trajectory of the meeting and its attendant events. Biopharma executives and their colleagues in communications and PR weighed in on what that means for 2021 and beyond. read more By Carly Helfand Gilead unveiled a surprise Monday: It enjoyed a bigger-than-expected sales boost from COVID-19 therapy Veklury, better known as remdesivir. But what changed since October, when Gilead last predicted 2020 sales? Hospitalizations are up fourfold—and Veklury use is way up, too. read more By Ben Adams German biotech CureVac shouldn’t be discounted from being a major COVID-19 vaccine player despite being at the tail end of the race to market. read more By Conor Hale Teladoc Health will launch a pilot demonstration of Dexcom’s wearable, continuous glucose monitoring systems, at no cost for patients with Type 2 diabetes. read more By Angus Liu Toward the end of 2020, AstraZeneca splashed out $39 billion for Alexion to expand its immunology presence. Now, the rare disease specialist is offering up more details about its plan to reach about $9 billion to $10 billion in sales by 2025. read more By Angus Liu Even after shelling out $74 billion for Celgene and $13.1 billion for MyoKardia, Bristol Myers Squibb still has “significant financial flexibility” for deal-making. Specifically, the company's shopping for "midsize bolt-on deals" that look a lot like the MyoKardia buy, CEO Giovanni Caforio said. read more By Ben Adams This time last year, the life science world descended into San Francisco for the 2020 J. P. Morgan healthcare conference, doing the normal things like blowing a whole year’s budget in one day for a hotel room, shaking hands, doing deals and, if you’re like us, asking questions. read more By Conor Hale Following its $8 billion pitch last year to acquire Grail and its upcoming multi-tumor blood test, Illumina is planning a deeper dive into cancer genomics with a slew of new biopharma development partnerships. read more By Eric Sagonowsky Sanofi CEO Paul Hudson came on the job touting his digital hopes for the company, and now he's aiming to take the French drugmaker to digital level 2.0 with renewed ambitions and a new digital chief, Arnaud Robert, who joined from outside the industry. read more By Beth Snyder Bulik Alnylam CEO John Maraganore officially has a new-and-lofty goal: Vault the RNAi-focused company into the top five biotechs by market cap. What'll that take? Six-plus products, more than 500,000 patients, 20 clinical programs and a 40% revenue boost by the end of 2025, he said Monday at the virtual JPM conference. read more By Eric Sagonowsky Typically in drug and vaccine development, first-to-market products command a big advantage that can deter follow-up products. Not so with COVID-19 vaccines, experts said Tuesday. There’s still plenty of need for new entrants, and some could bring their own advantages. read more By Amirah Al Idrus The two vaccines and multiple therapeutics cleared for emergency use aren't nearly enough to stop COVID-19. We need an arsenal of drugs that work in different ways to attack a complex, multifaceted illness, speakers on a Fierce JPM Week panel said. read more |
|
